RxDoctor Payments Data

Melanie Bozard, MD

Internal Medicine · Kokomo, INNPI 1437153145

Payments from drug & device makers

$407in general payments, 2019–2025

Across 16 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$184
  • Novo Nordisk$61
  • AbbVie$45
  • Johnson & Johnson$27
  • GSK$25
  • Supernus Pharmaceuticals, Inc.$24
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$407100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$407 in reported general payments places this provider in the 60th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$208,107
Medicare patients
426
Services billed
2,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban172$182,143
JardianceEmpagliflozin128$160,692
OzempicSemaglutide60$114,625
MounjaroTirzepatide77$104,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$92,992
TrulicityDulaglutide48$76,597
FarxigaDapagliflozin Propanediol57$49,090
JanuviaSitagliptin Phosphate50$44,084
XareltoRivaroxaban21$31,396
Combivent RespimatIpratropium/Albuterol Sulfate24$30,082
Lantus SolostarInsulin Glargine,hum.Rec.Anlog124$26,475
Breo ElliptaFluticasone/Vilanterol38$25,873
Repatha SureclickEvolocumab22$23,600
InvokanaCanagliflozin13$21,564
PremarinEstrogens, Conjugated27$19,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$11$209,581215 claims
GSKTrelegy Ellipta, Breo Ellipta$25$118,865109 claims
Novo NordiskOzempic$61$114,62560 claims
AstraZenecaFarxiga, Symbicort$184$58,97774 claims
Johnson & JohnsonXarelto, Invokana$27$52,96034 claims
AbbVieLinzess, Synthroid$45$21,76169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →